Nikola Vučević: Everything you need to know

Nikola Vučević

#4 C

Boston Celtics

Status

ACTIVE

STATS

Career Averages

PTS

REB

AST

BLK

STL

18.1

10.5

3.1

0.9

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	TD3	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2025-26	64	49	28.4	15.1	8.4	3.3	0.6	0.6	1.3	23	0	1.6	4.2	36.9%	4.6	8.3	55.7%	6.2	12.5	49.3%	1.2	1.5	82.8%	2.0	6.4	2.0	2.5	-42	57.4%
2024-25	73	72	31.2	18.5	10.1	3.5	0.7	0.8	1.6	45	1	1.8	4.4	40.2%	5.8	9.8	58.7%	7.5	14.2	53.0%	1.6	2.0	80.5%	2.4	7.6	2.2	2.2	-98	61.1%
2023-24	76	74	34.3	18.0	10.5	3.3	0.8	0.7	1.6	45	0	1.2	4.1	29.4%	6.5	11.8	55.0%	7.7	15.9	48.4%	1.4	1.7	82.2%	2.8	7.8	2.5	2.1	-180	54.0%
2022-23	82	82	33.5	17.6	11.0	3.2	0.7	0.7	1.7	51	1	1.5	4.2	34.9%	5.8	9.8	59.4%	7.3	14.0	52.0%	1.6	1.9	83.5%	1.9	9.1	2.2	1.9	-20	59.4%
2021-22	73	73	33.1	17.6	11.0	3.2	1.0	1.0	1.9	44	0	1.4	4.5	31.4%	6.1	11.3	53.7%	7.5	15.8	47.3%	1.3	1.7	76.0%	1.9	9.1	2.5	1.7	-52	53.3%
2020-21	70	70	33.5	23.4	11.7	3.8	0.7	0.9	1.8	48	2	2.5	6.3	40.0%	7.0	13.7	51.3%	9.5	19.9	47.7%	1.9	2.2	84.0%	2.1	9.6	2.0	2.1	-341	56.0%
2019-20	62	62	32.2	19.6	10.9	3.6	0.8	0.9	1.4	41	0	1.6	4.7	33.9%	6.4	12.0	53.1%	8.0	16.7	47.7%	2.1	2.7	78.4%	2.3	8.6	2.2	2.5	+52	54.9%
2018-19	80	80	31.4	20.8	12.0	3.8	1.1	1.0	2.0	60	1	1.1	2.9	36.4%	7.7	14.0	54.9%	8.8	16.9	51.8%	2.2	2.8	78.9%	2.8	9.2	2.0	1.9	+218	57.3%
2017-18	57	57	29.5	16.5	9.2	3.4	1.1	1.0	1.9	29	1	1.1	3.6	31.4%	5.9	11.2	52.7%	7.0	14.7	47.5%	1.4	1.6	81.9%	1.8	7.4	2.5	1.8	-30	53.3%
2016-17	75	55	29.6	14.6	10.4	2.8	1.0	1.0	1.6	0	0	0.3	1.0	30.7%	6.1	12.7	48.1%	6.4	13.7	46.8%	1.4	2.1	66.9%	2.3	8.0	2.4	1.8	+0	49.8%
2015-16	65	60	31.3	18.2	8.9	2.8	1.1	0.8	1.9	0	0	0.0	0.1	22.2%	8.2	16.0	51.2%	8.2	16.1	51.0%	1.7	2.3	75.3%	2.7	6.2	2.7	1.5	+0	53.1%
2014-15	74	74	34.2	19.3	10.9	2.0	0.7	0.7	2.0	1	0	0.0	0.1	33.3%	8.5	16.2	52.4%	8.5	16.3	52.3%	2.2	2.9	75.2%	3.2	7.7	3.0	1.0	+0	54.8%
2013-14	57	57	31.8	14.2	11.0	1.8	0.8	1.1	2.0	3	0	0.0	0.0	0.0%	6.2	12.2	50.7%	6.2	12.2	50.7%	1.8	2.4	76.6%	3.2	7.7	3.0	0.9	+0	53.6%
Career	908	865	31.9	18.1	10.5	3.1	0.9	0.9	1.7	390	6	1.1	3.1	35.1%	6.5	12.2	53.4%	7.6	15.4	49.7%	1.7	2.2	78.3%	2.4	8.1	2.4	1.8	-493	55.3%

Career Averages

PTS

REB

AST

BLK

STL

17.9

9.9

3.2

0.8

0.5

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2025-26	2	0	18.0	6.0	5.5	2.0	0.0	0.0	1.0	0	1.0	3.0	33.3%	1.0	2.0	50.0%	2.0	5.0	40.0%	1.0	1.0	100.0%	0.5	5.0	3.0	2.0	+6	55.1%
2021-22	5	5	36.2	19.4	12.4	3.2	1.2	0.4	1.6	4	2.6	8.4	31.0%	5.4	9.8	55.1%	8.0	18.2	44.0%	0.8	1.0	80.0%	2.8	9.6	2.8	2.0	-39	52.0%
2019-20	5	5	37.0	28.0	11.0	4.0	0.6	0.8	2.6	4	3.6	8.8	40.9%	7.6	13.4	56.7%	11.2	22.2	50.5%	2.0	2.2	90.9%	1.8	9.2	2.6	1.5	-48	60.4%
2018-19	5	5	29.4	11.2	8.0	3.0	1.0	0.4	2.6	1	0.6	2.6	23.1%	3.6	9.0	40.0%	4.2	11.6	36.2%	2.2	2.8	78.6%	1.8	6.2	2.4	1.2	-66	43.6%
Career	17	15	32.3	17.9	9.9	3.2	0.8	0.5	2.1	9	2.1	6.2	34.3%	5.0	9.7	51.5%	7.1	15.9	44.8%	1.6	1.9	84.4%	1.9	7.9	2.6	1.5	-147	53.7%

Preseason
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
10/16	MIN	W 126-120	23	13	10	2	0	0	3	4	1	25.0%	8	4	50.0%	12	5	41.7%	2	2	100.0%	2	8	0.7	-1	2	13	50.5%
10/14	DEN	L 124-117	23	5	10	4	1	0	5	3	1	33.3%	4	1	25.0%	7	2	28.6%	0	0	0.0%	3	7	0.8	-26	3	7	35.7%
10/12	MIL	L 127-121	24	6	9	3	0	0	1	4	0	0.0%	6	3	50.0%	10	3	30.0%	2	0	0.0%	1	8	3.0	-8	1	9	27.6%
10/7	CLE	W 118-117	18	3	6	1	0	0	1	2	0	0.0%	1	1	100.0%	3	1	33.3%	2	1	50.0%	1	5	1.0	+6	1	8	38.7%
Preseason Totals			22.6	6.8	8.8	2.5	0.3	0.0	2.5	3.3	0.5	15.4%	4.8	2.3	47.4%	8.0	2.8	34.4%	1.5	0.8	50.0%	1.8	7.0	1.0	-29	1.8	11.3	39.0%

Regular Season
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
4/9	NYK	L 112-106	23	10	5	2	0	0	2	4	2	50.0%	3	2	66.7%	7	4	57.1%	0	0	0.0%	1	4	1.0	+1	2	12	71.4%
4/7	CHA	W 113-102	22	2	7	2	0	2	1	5	0	0.0%	5	1	20.0%	10	1	10.0%	0	0	0.0%	1	6	2.0	+1	1	1	10.0%
4/5	TOR	W 115-101	13	4	4	1	0	0	2	2	0	0.0%	3	2	66.7%	5	2	40.0%	0	0	0.0%	2	2	0.5	-14	4	0	40.0%
3/6	DAL	W 120-100	1	0	0	0	0	0	0	0	0	0.0%	0	0	0.0%	0	0	0.0%	0	0	0.0%	0	0	0.0	-1	0	0	0.0%
3/4	CHA	L 118-89	16	7	4	1	1	0	0	3	1	33.3%	7	1	14.3%	10	2	20.0%	2	2	100.0%	1	3	0.0	-9	1	6	32.2%
3/2	MIL	W 108-81	26	10	5	7	1	0	0	4	0	0.0%	8	5	62.5%	12	5	41.7%	0	0	0.0%	0	5	0.0	+25	4	11	41.7%
3/1	PHI	W 114-98	20	11	12	0	1	0	1	6	3	50.0%	3	1	33.3%	9	4	44.4%	0	0	0.0%	3	9	0.0	-4	2	18	61.1%
2/27	BKN	W 148-111	25	28	11	4	1	0	1	3	3	100.0%	10	6	60.0%	13	9	69.2%	7	7	100.0%	1	10	4.0	+35	2	42	87.1%
2/25	DEN	L 103-84	22	2	8	1	0	0	0	4	0	0.0%	3	1	33.3%	7	1	14.3%	0	0	0.0%	1	7	0.0	-9	2	3	14.3%
2/24	PHX	W 97-81	19	8	4	2	1	0	1	3	0	0.0%	8	4	50.0%	11	4	36.4%	0	0	0.0%	1	3	2.0	-7	0	10	36.4%
2/22	LAL	W 111-89	20	9	8	0	0	1	0	0	0	0.0%	6	4	66.7%	6	4	66.7%	2	1	50.0%	0	8	0.0	+15	2	15	65.4%
2/19	GSW	W 121-110	27	9	5	0	1	1	0	2	1	50.0%	7	3	42.9%	9	4	44.4%	0	0	0.0%	3	2	0.0	+17	1	11	50.0%
2/11	CHI	W 124-105	26	19	11	3	2	1	4	5	4	80.0%	7	3	42.9%	12	7	58.3%	2	1	50.0%	3	8	0.8	+26	3	26	73.8%
2/8	NYK	L 111-89	23	11	6	0	1	0	2	6	1	16.7%	7	4	57.1%	13	5	38.5%	0	0	0.0%	1	5	0.0	-24	4	4	42.3%
2/6	MIA	W 98-96	27	11	12	4	0	2	2	1	0	0.0%	7	4	57.1%	8	4	50.0%	4	3	75.0%	6	6	2.0	+11	1	25	56.4%
2/1	MIA	L 134-91	22	12	2	1	0	1	1	3	0	0.0%	9	5	55.6%	12	5	41.7%	2	2	100.0%	2	0	1.0	-37	3	6	46.6%
1/29	MIA	L 116-113	37	15	10	3	0	0	2	5	1	20.0%	13	5	38.5%	18	6	33.3%	2	2	100.0%	3	7	1.5	+9	3	13	39.7%
1/28	IND	L 113-110	29	25	9	4	2	1	3	4	3	75.0%	13	7	53.8%	17	10	58.8%	2	2	100.0%	1	8	1.3	-11	3	29	69.9%
1/26	LAL	L 129-118	36	18	11	5	0	1	2	3	1	33.3%	7	5	71.4%	10	6	60.0%	5	5	100.0%	1	10	2.5	-3	2	28	73.8%
1/24	BOS	W 114-111	34	16	7	6	2	1	1	2	2	100.0%	8	5	62.5%	10	7	70.0%	0	0	0.0%	0	7	6.0	-7	1	26	80.0%
1/22	MIN	W 120-115	31	10	8	3	0	0	1	4	2	50.0%	6	1	16.7%	10	3	30.0%	2	2	100.0%	2	6	3.0	-6	3	11	46.0%
1/20	LAC	W 138-110	32	19	8	4	2	1	0	2	1	50.0%	10	7	70.0%	12	8	66.7%	2	2	100.0%	3	5	0.0	+16	1	33	73.8%
1/18	BKN	W 124-102	28	17	11	6	1	0	1	7	1	14.3%	11	7	63.6%	18	8	44.4%	0	0	0.0%	2	9	6.0	+20	3	23	47.2%
1/16	BKN	L 112-109	32	19	6	5	2	0	1	3	1	33.3%	11	8	72.7%	14	9	64.3%	0	0	0.0%	0	6	5.0	+8	1	28	67.9%
1/14	UTA	W 128-126	30	35	7	5	2	0	1	6	2	33.3%	16	12	75.0%	22	14	63.6%	6	5	83.3%	4	3	5.0	+0	1	41	71.0%
1/13	HOU	L 119-113	37	14	7	5	2	1	0	3	0	0.0%	16	7	43.8%	19	7	36.8%	0	0	0.0%	1	6	0.0	-10	3	14	36.8%
1/10	DAL	W 125-107	28	15	12	3	2	1	2	5	1	20.0%	6	5	83.3%	11	6	54.5%	2	2	100.0%	3	9	1.5	+9	2	26	63.1%
1/7	DET	L 108-93	32	20	16	4	1	0	1	6	2	33.3%	14	7	50.0%	20	9	45.0%	0	0	0.0%	7	9	4.0	-10	0	31	50.0%
1/5	BOS	L 115-101	36	15	15	7	0	1	2	5	3	60.0%	9	3	33.3%	14	6	42.9%	0	0	0.0%	3	12	3.5	-10	1	28	53.6%
1/3	CHA	L 112-99	33	28	7	8	1	0	2	4	3	75.0%	11	8	72.7%	15	11	73.3%	4	3	75.0%	0	7	4.0	-9	2	36	83.5%
1/2	ORL	W 121-114	35	17	10	5	0	0	1	3	1	33.3%	8	6	75.0%	11	7	63.6%	2	2	100.0%	2	8	5.0	-3	1	29	71.5%
12/31	NOP	W 134-118	33	17	8	5	0	0	0	5	2	40.0%	8	5	62.5%	13	7	53.8%	2	1	50.0%	0	8	0.0	+6	2	24	61.2%
12/29	MIN	L 136-101	30	23	5	2	0	0	3	5	3	60.0%	12	7	58.3%	17	10	58.8%	0	0	0.0%	0	5	0.7	-8	2	16	67.6%
12/27	MIL	L 112-103	25	16	7	1	1	1	2	4	2	50.0%	10	5	50.0%	14	7	50.0%	0	0	0.0%	2	5	0.5	-8	2	15	57.1%
12/26	PHI	W 109-102	28	7	7	1	1	0	0	2	1	50.0%	5	2	40.0%	7	3	42.9%	0	0	0.0%	2	5	0.0	+1	2	12	50.0%
12/23	ATL	W 126-123	30	21	10	4	1	0	0	5	1	20.0%	11	8	72.7%	16	9	56.3%	2	2	100.0%	1	9	0.0	+9	1	30	62.2%
12/21	ATL	W 152-150	30	13	5	6	0	3	1	6	1	16.7%	6	4	66.7%	12	5	41.7%	2	2	100.0%	1	4	6.0	+6	1	19	50.5%
12/19	CLE	W 136-125	32	24	15	2	2	1	1	6	2	33.3%	14	9	64.3%	20	11	55.0%	0	0	0.0%	5	10	2.0	+15	1	34	60.0%
12/17	CLE	W 127-111	28	20	9	4	1	2	1	4	2	50.0%	10	7	70.0%	14	9	64.3%	0	0	0.0%	1	8	4.0	+15	0	31	71.4%
12/14	NOP	L 114-104	30	12	8	4	0	0	0	6	2	33.3%	10	3	30.0%	16	5	31.3%	0	0	0.0%	3	5	0.0	-11	4	7	37.5%
12/12	CHA	W 129-126	21	13	3	4	1	0	1	2	1	50.0%	6	5	83.3%	8	6	75.0%	1	0	0.0%	0	3	4.0	-15	0	18	77.0%
12/7	GSW	L 123-91	24	9	6	3	0	1	2	6	1	16.7%	7	3	42.9%	13	4	30.8%	0	0	0.0%	1	5	1.5	-28	1	7	34.6%
12/5	IND	L 120-105	26	8	4	2	0	0	0	3	2	66.7%	4	1	25.0%	7	3	42.9%	0	0	0.0%	0	4	0.0	-10	1	9	57.1%
12/3	BKN	L 113-103	33	16	11	0	0	2	6	6	1	16.7%	12	5	41.7%	18	6	33.3%	4	3	75.0%	3	8	0.0	-5	2	13	40.5%
12/1	ORL	L 125-120	34	20	11	5	0	2	2	2	1	50.0%	11	8	72.7%	13	9	69.2%	2	1	50.0%	4	7	2.5	+12	4	27	72.0%
11/29	IND	L 103-101	30	16	8	6	0	1	0	5	2	40.0%	9	3	33.3%	14	5	35.7%	4	4	100.0%	3	5	0.0	-7	1	23	50.8%
11/28	CHA	L 123-116	30	13	14	3	0	1	2	5	1	20.0%	6	5	83.3%	11	6	54.5%	0	0	0.0%	4	10	1.5	+12	3	21	59.1%
11/22	WAS	W 121-120	27	28	12	2	0	0	1	7	3	42.9%	13	9	69.2%	20	12	60.0%	1	1	100.0%	9	3	2.0	-1	4	32	68.5%
11/21	MIA	L 143-107	20	6	4	3	0	0	1	4	0	0.0%	4	2	50.0%	8	2	25.0%	2	2	100.0%	0	4	3.0	-9	1	5	33.8%
11/19	POR	W 122-121	33	27	8	2	1	1	3	9	5	55.6%	10	6	60.0%	19	11	57.9%	0	0	0.0%	1	7	0.7	-2	2	26	71.1%
11/17	DEN	W 130-127	29	8	9	6	0	1	1	8	2	25.0%	5	1	20.0%	13	3	23.1%	0	0	0.0%	1	8	6.0	-12	4	10	30.8%
11/16	UTA	L 150-147	41	21	12	2	3	0	0	8	3	37.5%	9	5	55.6%	17	8	47.1%	2	2	100.0%	0	12	0.0	-3	3	28	58.7%
11/12	DET	L 124-113	25	6	6	3	0	0	3	4	0	0.0%	6	3	50.0%	10	3	30.0%	0	0	0.0%	1	5	1.0	-10	1	6	30.0%
11/10	SAS	L 121-117	28	11	8	6	0	0	1	5	3	60.0%	9	1	11.1%	14	4	28.6%	2	0	0.0%	2	6	6.0	-14	2	9	37.0%
11/8	CLE	L 128-122	29	9	5	4	0	2	2	2	0	0.0%	9	4	44.4%	11	4	36.4%	2	1	50.0%	1	4	2.0	-23	4	6	37.9%
11/7	MIL	L 126-110	31	16	6	1	0	1	2	3	2	66.7%	10	5	50.0%	13	7	53.8%	0	0	0.0%	0	6	0.5	-11	3	13	61.5%
11/4	PHI	W 113-111	31	19	10	0	1	1	1	5	1	20.0%	9	7	77.8%	14	8	57.1%	2	2	100.0%	3	7	0.0	+8	1	25	63.8%
11/2	NYK	L 128-116	32	17	14	4	1	0	3	4	3	75.0%	6	3	50.0%	10	6	60.0%	2	2	100.0%	4	10	1.3	-11	3	27	78.1%
10/31	NYK	W 135-125	30	26	7	2	0	0	1	8	4	50.0%	9	6	66.7%	17	10	58.8%	5	2	40.0%	2	5	2.0	-3	3	24	67.7%
10/29	SAC	W 126-113	32	13	14	7	0	1	0	3	1	33.3%	9	4	44.4%	12	5	41.7%	2	2	100.0%	3	11	0.0	+16	1	30	50.5%
10/27	ATL	W 128-123	33	17	17	9	0	2	3	4	1	25.0%	7	6	85.7%	11	7	63.6%	2	2	100.0%	4	13	3.0	+11	3	36	71.5%
10/25	ORL	W 110-98	31	15	8	2	1	0	4	1	1	100.0%	6	4	66.7%	7	5	71.4%	4	4	100.0%	1	7	0.5	-4	3	21	85.6%
10/22	DET	W 115-111	32	28	14	2	0	1	1	6	4	66.7%	12	7	58.3%	18	11	61.1%	2	2	100.0%	4	10	2.0	+8	2	36	74.2%
Regular Season Totals			28.6	15.1	8.5	3.3	0.6	0.6	1.3	4.2	1.5	36.5%	8.3	4.6	55.5%	12.6	6.2	49.1%	1.4	1.2	83.5%	2.0	6.5	2.4	-57	2.0	22.0	57.1%

Postseason
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
4/21	PHI	L 111-97	18	9	5	1	0	0	0	4	1	25.0%	3	2	66.7%	7	3	42.9%	2	2	100.0%	1	4	0.0	-7	2	11	57.1%
4/19	PHI	W 123-91	17	3	6	3	0	0	2	2	1	50.0%	1	0	0.0%	3	1	33.3%	0	0	0.0%	0	6	1.5	+13	4	5	50.0%
Postseason Totals			17.9	6.0	5.5	2.0	0.0	0.0	1.0	3.0	1.0	33.3%	2.0	1.0	50.0%	5.0	2.0	40.0%	1.0	1.0	100.0%	0.5	5.0	2.0	+6	3.0	11.0	55.1%

Nikola Vučević: Breaking News

Vucevic provided nine points (3-7 FG, 1-4 3Pt, 2-2 FT), five rebounds and one assist over 18 minutes during Tuesday's 111-97 loss to the 76ers in Game 2 of the first round of the Eastern Conference playoffs. Vucevic continues to play a limited role off the bench, providing Boston with modest production on both ends of the floor. The fact that he is playing purely as a backup despite the fact that Neemias Queta has been struggling highlights just how unimpactful Vucevic has been.

Vucevic (finger) is not listed on the injury report ahead of Game 1 against the 76ers on Sunday. Vucevic missed 14 consecutive games from March 8 to April 3 due to a fractured right index finger. He returned to action April 5 and appeared in four games before sitting out the Celtics' regular-season finale against the Magic this past Sunday, and he'll be available for the start of Boston's playoff run. Vucevic will likely serve as the top big man off the bench behind starting center Neemias Queta.

Vucevic (finger) has been ruled out for Sunday's game against the Magic, Justin Turpin of WEEI.com reports. Vucevic has played in each of Boston's last four games after missing 14 consecutive games from March 8 to April 3 due to a fractured right index finger. The Celtics are locked in as the No. 2 seed in the Eastern Conference standings, so with nothing to play for, Vucevic and several other key players for Boston will sit for Sunday's regular-season finale. Across 16 regular-season games (one start) with the Celtics, the veteran big man averaged 9.7 points, 6.6 rebounds, 2.0 assists and 1.1 threes over 21.1 minutes per contest. With Vucevic and Neemias Queta (toe) both sidelined, Luka Garza and Amari Williams will both see significant playing time against Orlando.